/

CRDL

Cardiol Therapeutics Inc.After hours

1.14−0.06 −5.00%USD

NasdaqCM · as of Oct 14, 16:00 ET · 15m delay

Open

1.20

Prev close

1.20

Day range

1.131.20

52-week range

0.88002.34

Volume

683.32K0.47×

Mkt cap

138.52M

P/E ttm

—

Fwd P/E

-4.98

EPS ttm

-0.2500

Div yield

0.00%

Earnings

—

From 52w high

−51.28%

Price Chart

Yahoo Finance · delayed

CRDLOct 14, 2026O 1.20H 1.20L 1.13C 1.14−0.06 (−5.00%)Vol 683.32K

SMA 501.74
SMA 2001.29

1Y change +8.57% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CRDL Cardiol Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −13.64%
1 month: −42.71%
3 months: +2.70%
6 months: −20.28%
Year to date: +19.50%
1 year: +9.62%

Valuation & ownership

Market cap: 138.52M
Enterprise value: 114.21M
P/E (ttm): —
Forward P/E: -4.98
PEG ratio: —
Price / book: 7.87
Price / sales (ttm): —
EV / EBITDA: -3.19
EPS (ttm): -0.2500
EPS (forward): -0.2288
Beta (5y monthly): 0.72
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 121.51M
Float: 91.98M
Short % of float: 2.59%
Short ratio (days): 2.51
Held by insiders: 2.27%
Held by institutions: 26.38%
Avg volume (3m): 1.45M
50-day average: 1.75
200-day average: 1.29
52-week change: +9.62%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 20.9
vs 50-day SMA: −34.56%
vs 200-day SMA: −11.90%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.59%
Realised vol (20d, ann.): 51.1%
From 52-week high: −51.28%
From 52-week low: +29.55%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

8.43

+639.87% implied

Low 4.97Median 8.89High 11.02

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0

DES

About Cardiol Therapeutics Inc.

Yahoo Finance profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 18
Headquarters: Oakville, ON, Canada
Website: cardiolrx.com
Officers: Mr. David G. Elsley MBA President, CEO & Director
Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA CFO, Corporate Secretary & Director
Mr. Bernard Lim B.Sc. Chief Operating Officer
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer and Head of Research & Development

SEAS

Seasonality · CRDL

2019–2026 · monthly returns

Strongest month Jan +15.29%Weakest month Mar −12.03%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.3	7.3	32.4	2.2	-11.6	-13.1	19.8	55.5	-15.9	-31.3			+19.5%
2025	10.2	-18.4	-15.7	13.4	13.6	8.8	9.6	-27.5	-0.9	5.6	-7.1	-9.1	−25.5%
2024	44.7	68.9	-12.1	11.0	30.3	-22.9	6.9	-10.2	2.1	-9.1	-10.0	-21.0	+51.8%
2023	38.0	-24.7	-8.1	27.3	8.7	32.0	21.3	1.9	-18.6	-7.3	10.5	-8.1	+65.3%
2022	0.0	-9.2	-8.9	-10.5	-2.2	-1.5	0.0	-15.2	-8.0	-41.8	-14.0	-1.0	−72.4%
2021	12.8	41.5	0.6	-1.4	-21.2	-11.8	-6.3	66.2	11.0	-12.8	-44.8	-7.5	−15.1%
2020	-14.0	-24.9	-10.5	2.8	-3.8	-13.4	1.8	27.0	0.4	-1.1	-8.7	6.3	−38.3%
2019		33.4	-29.4	1.0	-29.6	13.1	6.7	-10.9	-26.8	3.1	25.8	16.1	−20.7%

INSD

Insider Activity · CRDL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 7, 2026	Torreamione (Guilermo)Senior Officer of Issuer	Exercise of warrants at price 1.35 per share.	25K	$33.75K
Aug 27, 2026	Hamer (Andrew Warwick M.D.)Senior Officer of Issuer	—	70K	—
Aug 20, 2026	Chao (Jennifer M)Director of Issuer	—	13.3K	—
Aug 20, 2026	Loxam (Teri)Director of Issuer	—	13.3K	—
Oct 16, 2025	Elsley (David)Director of Issuer	Acquisition carried out privately at price 1.00 per share.	100K	$100.00K
Oct 16, 2025	Torreamione (Guilermo)Senior Officer of Issuer	Acquisition carried out privately at price 1.00 per share.	50K	$50.00K

13F

Investors Holding CRDL

latest 13F filings of 29 followed managers

Investors holding CRDL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$819.2K	0.00%	772.84K	+236%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CRDL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CRDL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cardiol Therapeutics Inc.

Seasonality · CRDL

Insider Activity · CRDL

Congress Trades · CRDL

Investors Holding CRDL

Investors Holding CRDL

Congress Trades · CRDL

Insider Activity · CRDL

Seasonality · CRDL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cardiol Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News